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Disease-modifying therapies (DMTs) are urgently needed to treat the growing number of individuals 
with Alzheimer’s disease (AD) or at immanent risk for AD.  A definition of DMT is required to 
facilitate the process of DMT drug development. 
Process:   
This is an expert opinion review of the state of the science with regard to definition and development of 
DMTs. 
Results: 
A DMT is as an intervention that produces an enduring change in the clinical progression of AD by 
interfering in the underlying pathophysiological mechanisms of the disease process that lead to cell 
death.  Demonstration of DMT efficacy is garnered through clinical trial designs and biomarkers. 
Evidence of disease modification in the drug development process is based on clinical trial designs such 
as staggered start and delayed withdrawal or on combined clinical outcomes and correlated biomarker 
evidence of an effect on the underlying pathophysiological processes of the disease.  Analytic 
approaches such as showing change in slope of cognitive decline, increasing drug-placebo difference 
over time, and delay of disease milestones are not conclusive by themselves but support the presence of 
a disease modifying effect.    Neuroprotection is a related concept whose demonstration depends on 
substantiating disease modification.  No single type of evidence in itself is sufficient to prove disease 
modification – consistency, robustness, and variety of sources of data will all contribute to convincing 
stakeholders that an agent is a DMT.  
Conclusion: 
 DMT is defined by its enduring effect on processes leading to cell death.  A variety of types of data can 
be used to support the claim that disease modification has occurred.   
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Defining Disease Modifying Therapy for Alzheimer’s Disease 
 Disease-modifying therapy (DMT) is a major goal of research in Alzheimer’s disease (AD) 
therapeutics.  People with or at risk for AD, caregivers and family members, academic scientists, 
advocacy groups, biopharma industry scientists, the National Institutes of Health and other funders, and 
regulatory agencies are all stakeholders in the search for drugs or other interventions that can prevent or 
defer the onset or slow the decline of AD.  Putative DMTs build on an increasingly sophisticated 
neurobiological understanding of AD and intervene in steps thought to be critical to the 
pathophysiological process leading to cell death that expresses itself clinically as disease progression.  
The search for DMTs has taken on increased urgency as the world faces the tsunami of AD occurring 
with the aging of the global population.[1]  Simultaneously, the discovery of the long preclinical phase 
of AD has revealed the great number of people who have AD-type changes in the brain and are at risk 
for the emergence of clinical manifestations.[2, 3]   DMTs are warranted in this population to prevent or 
defer disease emergence. 
 Despite the obvious need for treatments that will change the course of AD, the large number of 
programs directed at finding such agents, and the size of the population involved or at risk there has 
been relatively little discussion or consensus building about the definition of DMT or the data needed to 
meet the definition.  Much of the information is in regulatory documents.[4, 5]  A definition is necessary 
to identifying appropriate clinical outcomes, develop biomarkers, and design trials that will demonstrate 
disease modification and meet agreed upon criteria.   
 In this paper, we address key issues of the concept of disease modification and DMTs and offer a 
framework for collecting data in clinical trials supportive of disease modification by the candidate 
therapy. 
Defining Disease-Modifying Therapy 
   The three key elements of DMT are disease, modifying, and treatment.[4-6]    
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”Disease” includes the preclinical phase of AD when there is evidence of fibrillar amyloid 
deposition in the brain on amyloid imaging or abnormally low levels of the 42 amino acid amyloid beta 
protein (AB42) in cerebrospinal fluid (CSF) and the subject has normal cognition and function; 
prodromal AD identified by the presence of the same Aß abnormalities in individuals who have some 
degree of cognitive impairment but do not meet criteria for dementia; and individuals with biological 
and clinical evidence of AD dementia.[7, 8] Figure 1 shows the populations of AD in which DMT 
development is being pursued.  There is a lack of consensus on whether the preclinical phase as 
described here is properly considered a disease since there are no symptoms, but treatments provided in 
this stage are aimed at preventing the symptomatic phases of AD and can be considered as DMTs.  
Preclinical applications of DMTs can include both primary prevention, beginning with individuals who 
have no evidence of AD pathology, or secondary prevention in individuals who are cognitively normal 
but have positive amyloid imaging or other biomarker evidence of the presence of AD pathology.   
 
Figure 1.  Stages of Alzheimer’s disease applicable to development of disease modifying therapies. 
 
“Modifying” is the key word in the definition of DMT and is considered in more detail 
throughout this paper.  The concept of modification is based on extrapolation from basic science 
observations that have identified processes in cellular studies, animal models, or human pluripotent stem 
cells (iPSCs) that result in AD-like changes and that can be altered by treatment.[9, 10]  For human 
application, “modification” refers to a change in the underlying disease process that produces an 
enduring effect on the clinical course of AD. Pathological processes of AD possibly contributing to cell 
death and representing targets for DMT’s include disruption of membrane integrity, inflammation, 
oxidation, apoptosis, mitochondrial dysfunction, synaptic loss, cell loss, heavy metal-related facilitation 
of neuronal injury, demyelination, and possibly other processes yet to be identified.  
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“Therapy” refers to a structured intervention that might include a pharmacologic agent, device, 
or nonpharmacologic activity such as exercise.[11]   
Disease modification is an inferential concept based on trial-derived data since direct observation 
of the changes in the brain is not feasible. The data necessary to provide evidence of an enduring clinical 
effect and disease modification are generated in clinical trials using clinical outcomes and biomarkers.  
Trial design and analytic strategies are used to optimize the ability to demonstrate drug-placebo 
differences.   
The concept of DMT stands in contrast to the idea of “symptomatic” therapy defined as 
interventions that improve cognition, defer cognitive or functional decline, or ameliorate symptoms such 
as agitation, depression or delusions without altering the underlying disease processes that comprise AD 
pathogenesis and without producing enduring changes that persist when the treatment is withdrawn.  
Symptomatic therapies may be based on disease-related concepts such as a cholinergic deficiency but 
are not intended to interrupt processes leading to cell death.  Symptomatic treatments such as 
cholinesterase inhibitors have been shown to delay disease progression as measured by cognitive and 
functional measures[12], and delay of symptoms does not constitute proof of disease-modification.   
Based on the critical elements, a DMT can be defined as an intervention that produces an 
enduring change in the clinical progression of AD by interfering in the underlying pathophysiological 
mechanisms of the disease process leading to cell death.  Data supporting an intervention as a DMT 
would meet one of two criteria: 1) the intervention produces a significant drug-placebo difference on 
accepted clinical outcome(s) and has a consistent effect on one or more validated biomarkers considered 
fundamental to AD pathophysiology, or 2) the intervention produces a positive outcome on a staggered 
start or delayed withdrawal clinical trial design consistent with an enduring change in clinical course.    
The interpretation of biomarker results will depend on the repertoire of biomarkers tested, their internal 
consistency, relationship to the proposed mechanism of action, dose-response observations, and effect 
on proposed “downstream” events.  This DMT definition is not the same as specifying the requirements 
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for approval of a DMT by a regulatory body; regulatory agencies address such issues as the necessary 
number of trials, quality of trials and trial data, and clinical meaningfulness of the observations.  
Disease modification has synergies with the concept of “neuroprotetction.”  The latter refers to 
interventions that favorably influence the disease process or underlying pathogenesis to produce 
enduring benefits for patients.[13, 14]  The clinical benefit is achieved by forestalling onset of illness or 
clinical decline. Effective neuroprotection results in disease modification and efficacious 
neuroprotective therapies are disease-modifying.   Neuroprotection may be primary if the mechanism of 
action is directly on the neuron (e.g., mitochondrial agents) or secondary if the protection is derived 
from an action on an intermediary that compromises neuronal function.  Neuroprotection achieved with 
multiple sclerosis therapies, for example, is proposed as secondary neuroprotection from effects on 
inflammation. 
 Neuroprotection and disease modification are concepts that apply broadly across 
neurodegenerative diseases.[15, 16] 
 
Regulatory Views of Disease Modification 
In its guidance on “Alzheimer’s Disease:  Developing Drugs for Treatment of Early Stage 
Disease”[4]  the US Food and Drug Administration (FDA) described two approaches to demonstrating 
disease modification:  1) clinical benefit supported by a meaningful effect on a biomarker, or 2) clinical 
trial design suited to demonstrating a lasting effect on the disease course.  They stated that a divergence 
of slope of decline might be produced by a pharmacologically reversible effect and is not by itself 
evidence of disease modification.  They noted that a biomarker effect must reflect a pathophysiological 
entity that is fundamental to the underlying disease process.  They observed that there is currently 
insufficient evidence on which to base a hierarchical structuring of biomarkers and encouraged trial 
sponsors to analyze the results of biomarkers independently.  The FDA guidance observed that 
randomized start and randomized withdrawal trial designs with clinical outcomes can provide evidence 
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of enduring effects consistent with disease modification. They stated that for ethical reasons, the 
randomized start design would be most appropriate for trials of patients with AD. 
 The European Medicines Agency (EMA) discussion of AD therapy states that a medicinal 
product can be considered to be disease modifying when it delays the underlying pathological or 
pathophysiological disease processes.[5]  It states that this can be demonstrated by results that show 
slowing of the rate of decline of clinical signs or symptoms when these results are linked to a significant 
effect on adequately validated biomarkers that reflect key pathophysiological aspects of the underlying 
disease process.  EMA noted that change in rate of decline as shown by slope analysis and increasing 
drug-placebo difference are analyses that can support a disease-modifying effect.  Delayed start or 
withdrawal designs were described as options to enhance the data derived from a trial intended to show 
disease modification.  EMA suggested that if biomarker results are unclear, an alternative treatment goal 
such as “delay or slowing in rate of decline” may be acceptable if effects on cognition and function are 
demonstrated. 
  
Trial Design and Data Analysis to Support Disease Modification 
 Delayed start and randomized withdrawal are clinical trial designs that provide evidence of 
disease modification.[17]  In the delayed  start design, one subject group is started on treatment later 
than another and the failure to “catch up” with the first indicates that there has been an enduring effect 
on the disease and the effect of the drug is more than symptomatic.  In the randomized withdrawal 
design, a treated subject group is withdrawn from therapy and if they do not assume the same level of 
function as an untreated group, then the disease has been modified.[18]  There are substantial 
uncertainties with these proposed designs such the appropriate duration of the period between the start 
of treatment of groups 1 and 2 in the delayed start and the required duration of the period of observation 
of the withdrawn group in the randomized withdrawal design.  No study has successfully utilized these 
designs to establish disease-modification in a neurodegenerative disorder.  
 9 
 In addition to the trial design, strategies for data analysis can contribute to supporting the 
presence of disease-modification in trials of DMTs.  Four major analytic approaches have been used in 
clinical trials:  1) drug-placebo difference at trial end; 2) delay to milestone (e.g, progression to Clinical 
Dementia Rating [CDR][19] to 1 from 0.5 or to 2 from 1); 3) increasing drug placebo difference over 
time; and 4) change in slope of decline.  Drug-placebo difference at trial end and delay to milestone are 
not unique to disease modification and can be produced by symptomatic agents.[12]  Change in slope 
from more acute to less acute with successful intervention and increasing drug-placebo difference over 
time are supportive of disease-modification (Figure 2).[18]  Neither of these are sufficiently informative 
by themselves to establish disease modification.  They are expected outcomes of a successful DMT trial 
and can add support to the case for disease modification.  EMA has suggested that these analyses might 
be supportive of a “slowing in rate of decline”[5]; that could serve as an alternative label for a candidate 
agent that failed to meet all criteria for a DMT.   
 
Figure 2.  Analytic observations consistent with disease modification. 
 
Clinical Outcomes to Demonstrate Disease Modification 
  A successful DMT must produce meaningful clinical benefit.  New outcome instruments are 
required to show the clinical dimension of disease-modification in newly identified trial populations 
such as those with normal cognition in prevention trials and those with mild cognitive changes in 
prodromal AD trials.  In primary prevention trials, DMTs would be expected to delay the development 
of biomarker evidence of AD (e.g, delay of amyloid accumulation as shown by amyloid imaging) and 
thereby to delay the onset of cognitive decline.  No biomarker has been shown to be a surrogate of 
clinical decline in AD and trials will be forced to use biomarkers that are “reasonably likely” to predict 
clinical benefit.  Such approaches have been used in development of drugs for other disease states such 
as human immunodeficiency virus infections.[20]  Confirmation of the disease modifying effect on 
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cognition would require observation of the treated patients for long periods of time. Primary prevention 
might be instituted at age 50 or 55, delayed amyloid deposition might be evident after 4-5 years of 
treatment, but delay of cognitive decline would require observation until age 65 of 70 – 20 years after 
the initiation of therapy.  These timeframes will require use of putative fit-for-purpose biomarkers that 
may eventually be shown to be predictive of cognitive function.  Biomarker effects by themselves if 
considered reasonably likely to predict clinical benefit might be sufficient for accelerated approval 
requiring demonstration of cognitive effects with longer term observation after approval.   
Secondary prevention trials enroll individuals who are cognitively normal but who have 
biomarker evidence (e.g., positive amyloid imaging, CSF signature of AD) of being at high risk for the 
development of cognitive decline.  The combination of delay of onset of cognitive decline compared to 
placebo and biomarker changes supportive of an impact on the fundamental pathophysiology of AD 
would be key to establishing an agent as a DMT.   
 Prodromal AD is the predementia stage of AD in which patients have cognitive impairment 
without functional deficits, do not meet criteria for dementia, and have a biomarker indicative of the 
presence of AD pathology (positive amyloid imaging; low CSF Aß42).[8]  The FDA has issued a 
guidance concerning trials in this population and has suggested the composite measures such as the 
Clinical Dementia Rating – Sum of Boxes (CDR-sb)[19] could function as a single trial outcome 
although benefit on both the cognitive and functional portions of the measure is expected.[4]  Several 
alternative composites have been proposed for this role including the integrated AD Rating Scale 
(iADRS)[21] and the AD Composite Scale (ADCOMS).[22]  Support for disease modification could be 
obtained by showing a drug-placebo difference at trial end on the composite score and on a suite of 
biomarkers, or the composite could be used as the outcome in a staggered start or randomized 
withdrawal trial design.  Expectations for functional outcomes in this population are ambiguous since 
the prodromal population by definition lacks functional impairment.   
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 DMTs would also be appropriate for treatment of AD dementia especially in early stages when 
cognitive and functional deficits remain compatible with acceptable quality of life.  In some studies, 
prodromal and mild AD dementia are included in the same trial population in recognition of the arbitrary 
nature of dividing the seamless spectrum of progressive cognitive decline that characterizes AD.  
Clinical outcomes in these populations would require showing a drug-placebo benefit on cognitive and 
functional or global outcomes.   The clinical outcomes would require support of biomarkers to establish 
an agent as a DMT.  Alternatively, the outcomes could be used in staggered start or randomized 
withdrawal designs. 
 Establishment of disease modification is dependent on the measurement characteristics of the 
tools (clinical and biomarker) used as well as the quality of execution of the clinical trial.   
 
Biomarkers to Demonstrate Disease Modification 
 There is currently a limited repertoire of biomarkers of AD and none have achieved the status of 
a surrogate marker that is known to reliably predict clinical outcomes and can be substituted for clinical 
measures in trials.  Two biomarkers have been qualified by the EMA and can be used in clinical trials 
without re-qualification for individual trials.  These are low CSF Aß42 and hippocampal atrophy as 
measured on magnetic resonance imaging (MRI ).[23, 24]  No AD biomarkers have been qualified by 
the FDA and biomarkers used as outcome measures in trials of DMTs must be established as fit-for-
purpose for each trial.[25]   
 Biomarkers can be divided into diagnostic biomarkers that identify the presence of AD type 
pathology and pathophysiological biomarkers that reflect disease progression.[8]  Recognized diagnostic 
biomarkers include amyloid imaging documenting abnormal amyloid levels and the CSF signature of 
AD comprised of low Aß42 and high tau or phospho-tau (p-tau). Biomarkers reflecting disease 
progression include measures of brain atrophy using MRI, assessment of cerebral metabolism using 
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fluorodeoxyglucose (FDG) positron emission tomography (PET), CSF levels of tau and p-tau, and tau 
PET.   
 Effects on diagnostic biomarkers do not by themselves support disease-modification.  
Bapineuzumab and AN-1792 are examples of immunotherapies that reduced plaque burden in clinical 
trials and did not affect the course of decline in AD.[26, 27]   Removal of plaque amyloid documents an 
effect of treatment on fibrillar amyloid but not necessarily an effect on processes leading to cell death.   
 Effects on biomarkers of disease progression could be regarded as evidence in support of 
disease-modification.  Reduction of whole brain or hippocampal atrophy compared to atrophy in a 
placebo group would be regarded as supportive of disease-modification if seen in conjunction with 
clinical benefit.  Several trials have shown greater atrophy in groups treated with putative DMTs 
compared to placebo controls and a comprehensive understanding of the influences on this measure has 
yet to be achieved.[28, 29]  Less elevation of CSF tau or p-tau in the treatment group compared to the 
placebo or reduced tau accumulation as seen on tau imaging would be regarded as evidence of disease 
modification.[30]  Less marked reduction of cerebral metabolism on FDG PET would support a disease-
modifying effect; this evidence should be viewed with caution as changes on FDG PET can be produced 
by symptomatic agents such as cholinesterase inhibitors.[31] 
 FDA has suggested that multiple biomarkers should be collected in clinical trials.  Assessing 
amyloid imaging and CSF Aß42 could provide internally consistent evidence of an effect on amyloid 
physiology.  Similarly, collecting simultaneous measures of tau abnormalities – tau imaging, CSF tau/p-
tau – might convincingly support a tau-related drug effect[32] as part of a data package supporting 
disease-modification. 
 Pathophysiological events in AD are hypothesized to be linked, with amyloid changes being 
“upstream” and tau alterations, inflammation and cell loss being “downstream”.[33]   Measures of 
several biomarkers that indicate effects on different elements of the pathophysiology would be 
supportive of a disease-modifying effect independent of the veracity of our current disease models.  
 13 
Thus, measures of Aß42, CSF tau/p-tau, and whole brain atrophy on MRI could provide a more 
comprehensive view of the effects of a DMT and a more compelling suite of observations.  The 
interpretation of biomarker results will depend on the repertoire of biomarkers tested, their internal 
consistency, relationship to the proposed mechanism of action, dose-response observations, and effect 
on proposed “downstream” events. 
 Linking the observed biomarker effect to the observed clinical effect is important to support the 
effects of a DMT.  Biomarker and clinical effects could be achieved through different mechanisms of 
drug action.[20]  A relationship between the clinical and biological effects is indicated by correlations 
between the magnitude of change on clinical and biomarker measures.  A dose-response relationship 
between administered dose or serum level and biomarker effect would provide further evidence of a 
causative relationship. 
 
Classifying Evidence in Support of Disease Modification 
Data supporting disease modification are inferential based on biomarkers of biological effects; 
no direct measures of disease modification are available.  No single piece of evidence will prove that an 
agent has produced disease modification.  Synthesis of clinical outcomes, biomarker outcomes, trial 
designs, and analytic strategies supported by preclinical studies of mechanism of action will be required 
to provide a comprehensive approach to DMTs (Table 1).   
 
Table 1.   Data supporting disease-modification by a putative DMT. 
 
 The combination of clinical and biological observations allows the construction of levels of 
evidence in support of disease modification collected in trials.  Staggered start and randomized 
withdrawal evidence is more compelling than parallel group designs, and effects on multiple 
independent biomarkers are more compelling that effects on single biomarkers or related biomarkers.  
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Table 2 presents an approach to classification of levels of evidence in support of a DMT for mild-
moderate AD trial outcomes; similar approaches could be applied to prevention trials and trials 
involving prodromal AD. 
 
Table 2.  Approach to levels of clinical and biomarker evidence in support of disease modification 
 
Summary 
 AD is increasingly well understood from a neurobiological perspective.  New targets are being 
identified as the processes involved in the disease are better defined.  More candidate molecules are 
being identified and entered into the AD therapeutic pipeline.[34]  Many of these agents are intended to 
be DMTs that will prevent, delay or slow the progression of AD.  Success in developing DMTs grows 
more urgent as the population of those with or at risk for AD increases.  A definition of DMT is key to 
advancing a therapeutic agenda.  The recommendations offered here for defining DMTs and providing 
data to support identification of DMTs are intended to assist in the critical process of developing DMTs. 
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Table 1.   Data supporting disease-modification by a putative DMT. 
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Trial design 
 Staggered start 
 Randomized withdrawal 
 Drug-placebo difference at trial completion on accepted clinical outcomes and validated biomarkers 
 Delay to clinical milestones with supporting biomarkers 
Supportive analyses of the trial data 
 Change in slope of decline over multiple observation points 
 Increasing drug-placebo difference over time 
 Biomarker changes correlated with clinical changes 
 Dose response relationship of clinical outcomes with the intervention 
 Delay to milestone (e.g., % of subjects with prodromal AD reaching CDR 1 at specified times) 
 In a modified delayed start design, observe if patients switched from placebo to active therapy when 
entering the open label extension phase of the study “catch up” with those on active treatment 
throughout the study 
Biomarker measures 
 Single biomarker outcomes reflecting an effect on underlying pathophysiology contributing to 
clinical progression 
 Multiple biomarker outcomes measuring one aspect of the disease (e.g, CSF Aß and amyloid 
imaging) 
 Multiple biomarker outcomes assessing downstream or independent effects of an intervention (e.g, 
CSF tau/p-tau or MRI following anti-amyloid treatment) 
 Dose-response relationship of biomarker changes with the intervention 
Non-clinical observations 
 Effect on mechanisms central to the proposed pathophysiology of AD 
Table 2.  Approach to levels of clinical and biomarker evidence in support of disease modification. 
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Population Level of 
Evidence 




A1 Delayed start or 
delayed withdrawal 
Significant effect on 
cognitive and 
functional or global 
measures 
Significant effects on 
several independent 
biomarkers 
 A2 Parallel group Significant effect on 
cognitive and 
functional or global 
measures 
Significant effects on 
several related 
biomarkers 
 B1 Delayed start or 
delayed withdrawal 
Significant effect on 
cognitive and 
functional measures 
Significant effects on 
one biomarker or 
biomarkers limited to 
one aspect of AD 
 B2 Parallel group Significant effect on 
cognitive and 
functional measures 
Significant effects on 
one biomarker or 
biomarkers limited to 
one aspect of AD 
 C1 Parallel group Trend on cognitive 
and functional 
measures 
Significant effects on 
several independent 
biomarkers 
 C2 Parallel group Trend on cognitive 
and functional 
measures 
Significant effects on 
one biomarker or 
biomarkers limited to 




Figure 1.  Stages of Alzheimer’s disease applicable to development of disease modifying therapies. 
 
Figure 2.  Analytic observations consistent with disease modification (the time of intervention with a 
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